| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Health Catalyst, Inc.
13D/A
HCAT · 42225T107
|
18.3% |
3/13/2026
Event 3/12/2026
|
||||
| First Light Asset Management, LLC | 17.5% | |||||
| Mathew P. Arens | 18.3% | |||||
| Schedule 13G · 14 securities · passive | ||||||
|
Neogenomics, Inc.
13G/A
NEO · 64049M209
|
6.9% |
11/16/2026
Event 9/30/2026
|
||||
| First Light Asset Management, LLC | 6.5% | |||||
| Mathew P. Arens | 6.9% | |||||
|
KORU Medical Systems, Inc.
13G/A
KRMD · 759910102
|
6.6% |
11/16/2026
Event 9/30/2026
|
||||
| First Light Asset Management, LLC | 6.3% | |||||
| Mathew P. Arens | 6.6% | |||||
|
TriSalus Life Sciences, Inc.
13G/A
TLSI · 89680M101
|
12.0% |
11/16/2026
Event 9/30/2026
|
||||
| First Light Asset Management, LLC | 12.0% | |||||
| Mathew P. Arens | 12.0% | |||||
|
NeuroPace Inc
13G/A
NPCE · 641288105
|
12.3% |
9/4/2026
Event 8/31/2026
|
||||
| First Light Asset Management, LLC | 11.8% | |||||
| Mathew P. Arens | 12.3% | |||||
|
Axogen, Inc.
13G/A
AXGN · 05463X106
|
7.6% |
8/14/2026
Event 6/30/2026
|
||||
| First Light Asset Management, LLC | 7.0% | |||||
| Mathew P. Arens | 7.6% | |||||
|
Palvella Therapeutics, Inc.
13G/A
PVLA · 697947109
|
5.3% |
8/14/2026
Event 6/30/2026
|
||||
| First Light Asset Management, LLC | 5.3% | |||||
| Mathew P. Arens | 5.3% | |||||
|
SI-BONE, Inc.
13G/A
SIBN · 825704109
|
18.4% |
5/7/2026
Event 4/30/2026
|
||||
| First Light Asset Management, LLC | 18.0% | |||||
| Mathew P. Arens | 18.4% | |||||
|
908 Devices Inc.
13G/A
MASS · 65443P102
|
17.1% |
2/17/2026
Event 12/31/2025
|
||||
| First Light Asset Management, LLC | 16.5% | |||||
| Mathew P. Arens | 17.1% | |||||
|
Organogenesis Holdings Inc.
13G/A
ORGO · 68621F102
|
3.1% |
2/17/2026
Event 12/31/2025
|
||||
| First Light Asset Management, LLC | 2.9% | |||||
| Mathew P. Arens | 3.1% | |||||
|
Simulations Plus, Inc.
13G
SLP · 829214105
|
13.2% |
2/6/2026
Event 1/31/2026
|
||||
| First Light Asset Management, LLC | 13.2% | |||||
| Mathew P. Arens | 13.2% | |||||
|
AnaptysBio Inc.
13G/A
ANAB · 032724106
|
3.1% |
11/14/2025
Event 9/30/2025
|
||||
| First Light Asset Management, LLC | 2.8% | |||||
| Mathew P. Arens | 3.1% | |||||
|
Performant Healthcare, Inc.
13G/A
PHLT · 71377E105
|
16.4% |
8/14/2025
Event 6/30/2025
|
||||
| First Light Asset Management, LLC | 15.4% | |||||
| Mathew P. Arens | 16.4% | |||||
|
Paragon 28, Inc.
13G/A
FNA · 69913P105
|
1.7% |
3/7/2025
Event 2/28/2025
|
||||
| First Light Asset Management, LLC | 1.2% | |||||
| Mathew P. Arens | 1.7% | |||||
|
OptimizeRx Corporation
13G/A
OPRX · 68401U204
|
0% |
1/8/2025
Event 12/31/2024
|
||||
| First Light Asset Management, LLC | 0% | |||||
| Mathew P. Arens | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.